Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.ijid.2020.05.085

http://scihub22266oqcxt.onion/10.1016/j.ijid.2020.05.085
suck pdf from google scholar
32479865!7258847!32479865
unlimited free pdf from europmc32479865    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32479865      Int+J+Infect+Dis 2020 ; 97 (ä): 7-10
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Lack of antiviral activity of darunavir against SARS-CoV-2 #MMPMID32479865
  • De Meyer S; Bojkova D; Cinatl J; Van Damme E; Buyck C; Van Loock M; Woodfall B; Ciesek S
  • Int J Infect Dis 2020[Aug]; 97 (ä): 7-10 PMID32479865show ga
  • OBJECTIVES: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. METHODS: Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for the treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. RESULTS: DRV showed no antiviral activity against SARS-CoV-2 at clinically relevant concentrations (EC(50) > 100 muM). Remdesivir, used as a positive control, demonstrated potent antiviral activity (EC(50) = 0.38 muM). CONCLUSIONS: Overall, the data do not support the use of DRV for the treatment of COVID-19.
  • |*Coronavirus Infections/drug therapy[MESH]
  • |*Pandemics[MESH]
  • |*Pneumonia, Viral/drug therapy[MESH]
  • |Antiviral Agents/therapeutic use[MESH]
  • |Betacoronavirus/*drug effects[MESH]
  • |COVID-19[MESH]
  • |Cell Line[MESH]
  • |Cell Survival/drug effects[MESH]
  • |Darunavir/*therapeutic use[MESH]
  • |Humans[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box